* MAPREG *
2000 - IDF
Le Kremlin-Bicêtre
(near Paris)
www.mapreg.com Discovery, Drugs
Key words: Microtubules, CNS diseases, Spinal cord injury, Traumatic brain injury, Neurosteroids
Mission: to dscover new drugs based on a novel mechanism for the protection and repair of nerve connections
Clients: Pharmaceutical industry (own development up to phase II included)
denis.le-bouteiller@mapreg.com
Age: 11 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Academic |
Managing Dir.-CEO: Baulieu (Etienne Emile) [born 1926, M.D., Ph.D.]
Sc.Dir.-CSO: Robel (Paul) [M.D.]
Oper.Dir.-COO: Baeuerle (Ralf) [PhD]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): | Turnover (M€) : 0.031 (2009)
Total funding (M€) : 2.0
Last funding (M€) : n.a.
Focus : CNS
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2008 .03 | Round-financing : in preparation, with nomination of next CEO | RFIN | [7 years] |
| 2008 .02 | Registration : orphan Drug designation by EMEA for MAP4343 (trauma of spinal cord) | MKTG | [7 years] |
| 2000 .10 | Company founded by Etienne Emile Baulieu and his team at Kremlin-Bicêtre hospital (Paul Robel, Arlette Fellous, Pascal Azadian), within Inserm premises and support | ORGF | [0 year] | Actualisation / Updating: 3-May-2011 |
|
